These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

563 related items for PubMed ID: 26597311

  • 1. Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy.
    Labrie F, Derogatis L, Archer DF, Koltun W, Vachon A, Young D, Frenette L, Portman D, Montesino M, Côté I, Parent J, Lavoie L, Beauregard A, Martel C, Vaillancourt M, Balser J, Moyneur É, Members of the VVA Prasterone Research Group.
    J Sex Med; 2015 Dec; 12(12):2401-12. PubMed ID: 26597311
    [Abstract] [Full Text] [Related]

  • 2. Lack of influence of dyspareunia on the beneficial effect of intravaginal prasterone (dehydroepiandrosterone, DHEA) on sexual dysfunction in postmenopausal women.
    Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Gilbert L, Martel C, Balser J.
    J Sex Med; 2014 Jul; 11(7):1766-85. PubMed ID: 24774442
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
    Labrie F, Archer DF, Koltun W, Vachon A, Young D, Frenette L, Portman D, Montesino M, Côté I, Parent J, Lavoie L, Beauregard A, Martel C, Vaillancourt M, Balser J, Moyneur É, VVA Prasterone Research Group.
    Menopause; 2016 Mar; 23(3):243-56. PubMed ID: 26731686
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
    Labrie F, Archer DF, Koltun W, Vachon A, Young D, Frenette L, Portman D, Montesino M, Côté I, Parent J, Lavoie L, BSc AB, Martel C, Vaillancourt M, Balser J, Moyneur É, members of the VVA Prasterone Research Group.
    Menopause; 2018 Nov; 25(11):1339-1353. PubMed ID: 30358731
    [Abstract] [Full Text] [Related]

  • 5. Effect of intravaginal dehydroepiandrosterone (DHEA) on the female sexual function in postmenopausal women: ERC-230 open-label study.
    Bouchard C, Labrie F, Derogatis L, Girard G, Ayotte N, Gallagher J, Cusan L, Archer DF, Portman D, Lavoie L, Beauregard A, Côté I, Martel C, Vaillancourt M, Balser J, Moyneur E, VVA Prasterone Group.
    Horm Mol Biol Clin Investig; 2016 Mar; 25(3):181-90. PubMed ID: 26725467
    [Abstract] [Full Text] [Related]

  • 6. Influence of treatment of vulvovaginal atrophy with intravaginal prasterone on the male partner.
    Labrie F, Montesino M, Archer DF, Lavoie L, Beauregard A, Côté I, Martel C, Vaillancourt M, Balser J, Moyneur E, other participating Members of the Prasterone Clinical Research Group.
    Climacteric; 2015 Mar; 18(6):817-25. PubMed ID: 26517756
    [Abstract] [Full Text] [Related]

  • 7. TX-004HR Improves Sexual Function as Measured by the Female Sexual Function Index in Postmenopausal Women With Vulvar and Vaginal Atrophy: The REJOICE Trial.
    Kingsberg SA, Derogatis L, Simon JA, Constantine GD, Graham S, Bernick B, Gasper G, Mirkin S.
    J Sex Med; 2016 Dec; 13(12):1930-1937. PubMed ID: 27692842
    [Abstract] [Full Text] [Related]

  • 8. Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women.
    Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Berger L, Gilbert L, Martel C, Balser J.
    Menopause; 2009 Dec; 16(5):923-31. PubMed ID: 19424093
    [Abstract] [Full Text] [Related]

  • 9. Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study.
    Labrie F, Archer DF, Bouchard C, Girard G, Ayotte N, Gallagher JC, Cusan L, Baron M, Blouin F, Waldbaum AS, Koltun W, Portman DJ, Côté I, Lavoie L, Beauregard A, Labrie C, Martel C, Balser J, Moyneur É, Members of the VVA Prasterone Group.
    Maturitas; 2015 May; 81(1):46-56. PubMed ID: 25771041
    [Abstract] [Full Text] [Related]

  • 10. Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone).
    Archer DF, Labrie F, Bouchard C, Portman DJ, Koltun W, Cusan L, Labrie C, Côté I, Lavoie L, Martel C, Balser J, VVA Prasterone Group.
    Menopause; 2015 Sep; 22(9):950-63. PubMed ID: 25734980
    [Abstract] [Full Text] [Related]

  • 11. Intravaginal Testosterone Improves Sexual Satisfaction and Vaginal Symptoms Associated With Aromatase Inhibitors.
    Davis SR, Robinson PJ, Jane F, White S, White M, Bell RJ.
    J Clin Endocrinol Metab; 2018 Nov 01; 103(11):4146-4154. PubMed ID: 30239842
    [Abstract] [Full Text] [Related]

  • 12. Comparison of intravaginal 6.5mg (0.50%) prasterone, 0.3mg conjugated estrogens and 10μg estradiol on symptoms of vulvovaginal atrophy.
    Archer DF, Labrie F, Montesino M, Martel C.
    J Steroid Biochem Mol Biol; 2017 Nov 01; 174():1-8. PubMed ID: 28323042
    [Abstract] [Full Text] [Related]

  • 13. Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial.
    Constantine G, Graham S, Portman DJ, Rosen RC, Kingsberg SA.
    Climacteric; 2015 Apr 01; 18(2):226-32. PubMed ID: 25252699
    [Abstract] [Full Text] [Related]

  • 14. Combined data of intravaginal prasterone against vulvovaginal atrophy of menopause.
    Labrie F, Archer DF, Martel C, Vaillancourt M, Montesino M.
    Menopause; 2017 Nov 01; 24(11):1246-1256. PubMed ID: 28640161
    [Abstract] [Full Text] [Related]

  • 15. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy.
    Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Berger L, Gilbert L, Martel C, Balser J.
    Menopause; 2009 Nov 01; 16(5):907-22. PubMed ID: 19436225
    [Abstract] [Full Text] [Related]

  • 16. Effects of vaginal administration of conjugated estrogens tablet on sexual function in postmenopausal women with sexual dysfunction: a double-blind, randomized, placebo-controlled trial.
    Bumphenkiatikul T, Panyakhamlerd K, Chatsuwan T, Ariyasriwatana C, Suwan A, Taweepolcharoen C, Taechakraichana N.
    BMC Womens Health; 2020 Aug 12; 20(1):173. PubMed ID: 32787848
    [Abstract] [Full Text] [Related]

  • 17. Serum levels of sex steroids and metabolites following 12 weeks of intravaginal 0.50% DHEA administration.
    Ke Y, Labrie F, Gonthier R, Simard JN, Bergeron D, Martel C, Vaillancourt M, Montesino M, Lavoie L, Archer DF, Balser J, Moyneur E, other participating Members of the Prasterone Clinical Research Group.
    J Steroid Biochem Mol Biol; 2015 Nov 12; 154():186-96. PubMed ID: 26291918
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of the acceptability of intravaginal prasterone ovule administration using an applicator.
    Montesino M, Labrie F, Archer DF, Zerhouni J, Côté I, Lavoie L, Beauregard A, Martel C, Vaillancourt M, Moyneur E, Balser J.
    Gynecol Endocrinol; 2016 Nov 12; 32(3):240-5. PubMed ID: 26634942
    [Abstract] [Full Text] [Related]

  • 19. Prasterone: A Review in Vulvovaginal Atrophy.
    Heo YA.
    Drugs Aging; 2019 Aug 12; 36(8):781-788. PubMed ID: 31290076
    [Abstract] [Full Text] [Related]

  • 20. Decreased efficacy of twice-weekly intravaginal dehydroepiandrosterone on vulvovaginal atrophy.
    Bouchard C, Labrie F, Archer DF, Portman DJ, Koltun W, Elfassi É, Grainger DA, Ayotte N, Cooper TA, Martens M, Waldbaum AS, Labrie C, Côté I, Lavoie L, Martel C, Balser J, VVA Prasterone Group.
    Climacteric; 2015 Aug 12; 18(4):590-607. PubMed ID: 25511551
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.